Ryufin

emeis

France · FR001400NLM4 · reports in EUR · Europe

The answers

From the annual report for the year to Dec 31, 2025. Each line says what it is based on.

Is it growing?Fair
Revenue +4.6% in the year to Dec 31, 2025, on the year before.
Is it a good business?To watch
It earned −21% on its shareholders' equity in the year to Dec 31, 2025.
Is it safe?To watch
Equity is 11% of its assets, and operations brought in cash in the year.
Is the price fair?n/a
Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.

The year

Year to Dec 31, 2025, consolidated, in EUR.

€5.9B

revenue

0.81%

operating margin

−€298M

net profit

Year by year

As filed; an earlier year can differ from its own report when the company restated it.

Dec 2022Dec 2023Dec 2024Dec 2025
Revenue€4.7B€5.2B€5.6B€5.9B
Operating profit−€4.3B−€919M−€38M€48M
Net profit to shareholders−€4.0B€1.4B−€412M−€298M
Earnings per share−€62.33€0.13n/an/a
Cash from operations€410M€366M€472M€680M
Capital spending€638M€315Mn/an/a
Cash€856M€645M€519M€337M
Total assets€14.5B€13.9B€13.4B€12.7B
Equity−€1.5B€1.9B€1.7B€1.4B

What they do

In the company's own words, from the annual report.

L’activité du Groupe se déploie dans une vingtaine de pays et couvre cinq métiers que sont les cliniques psychiatriques, les Cliniques de Soins Médicaux et de Réadaptation, les maisons de retraite, les services et soins à domicile et les résidences services.

Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.